Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...

The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...